# New tools for health data analysis

Sharon Naidoo & André Bellingan







System is structured to process claims and pay benefits

We have enormous amounts of data in the healthcare system that can be 30m used to improve performance

150m

65m

2.5m

Encounters between patients and healthcare provider

Pharmacy visits, with Nappi codes

Family practitioner visits, with RPL and ICD codes

Hospital admissions with ICD and CPT code strings, Nappi codes and utilisation data

### Conventional reporting



PLPM cost comparisons

Traditional age and gender

"Keeping score of a losing game"

Lack insight

"So what?"

### Clinical data hierarchy

Capturing diagnostic codes for all interventions allows tracking of disease burden. In South Africa this is done using **ICD 10** 

Treatment coding keeps track for the activity level in the health systems - how many consultations, how many hospital admissions with supporting detail like days in ICU wards and time in theatre.

Medicines and consumables are individually coded so as to be able to identify volumes, track efficacy, and ensure compliance with protocols and formularies.

*Risk scores* provide a way of monitoring risk profiles of populations over time, and comparing risk profiles between regions, considering the state of health and sickness of each patient in a summarized but meaningful way



consumables



### Diagnostic related groups (DRGs)

DRGs are a grouping tool that categorise hospital admissions into *clinically and actuarially meaningful groups*.

The applications of DRGs are primarily to quantify and monitor *cases* mix – changes in case mix over time, and comparisons of case mix differences between facilities.

This allows *like for like* comparisons to be done when comparing financial efficiency and outcomes over time or between two hospitals.











The episode grouper groups encounters with healthcare providers, as captured by claims to the medical scheme, into coherent episodes of care.











The Signal model compares benefit richness and price to allow for meaningful comparisons of value-formoney in the medical schemes market using objective quantitative methods.

The model allows for:

- Medical savings accounts
- Benefit limits
- Co-payments
- Self-payment gaps
- Above-threshold benefits



This is a visualisation of the referral network of GPs, specialists and hospitals in the Cape Town metro and surrounds.

Lines represent referral relationships and circles represent practices.



The size of a circle indicates how much "influence" that practice has.

In a social networking setting **influence** would relate to how many friends you have. Here it indicates how many different providers a practice has a referral relationship with

### Regional Analysis

### The Quality of Medical Care in the United States:

A Report on the Medicare Program



"It is not just who you are as a patient that determines what healthcare you receive but also where you live."

"There is a lot of unwarranted variation in clinical practice that is not explained by illness, medical need or the dictates of evidence based medicine."







Patients don't always travel to the facility that is closest to them.

Sometimes patients travel through or around the closest centre to access care.

National roads and freeways are important

Referral regions are not bound by municipal or provincial borders.

#### A note from PPO Serve

"For the regional analysis, a referral area is the defining the unit of analysis (comparison) for the health system at work. The objective of the exercise is understand variation, and therefore areas of improvement.

We achieve this by defining the correct numerator and denominator for each competing health system"







Statistical Model of medical scheme membership for each "small area" in South Africa. The model is populated with information from public data sources.

Estimated medical scheme population in Cape Town



Proportion of population

0,000 1,000

### Applications – Benchmarking providers





Direct costs per patient per month

0.00% 5.00% 10.00% 15.00% 20.00% 25.00% 30.00% 35.00% 40.00% 45.00% 50.00% 55 00% 60 00% 65 00% 70 00% % of male patients over the age of 45 that had a PSA test in the last two years

## Integrated tool set and applications for data driven decision making



Membership monitoring

Family Practitioner benchmarking

Specialist benchmarking

Hospital benchmarking

Sophisticated risk adjustment and attribution

Health provider network design

Market share and regional analytics

Alternative reimbursement models

Benefit richness analysis and benchmarking

Solutions deployed through an online dynamic system; with slice and dice functionality to empower users.

Sophisticated tools to manage a complex environment. Applied through actuarial services, managed care analytics, and strategic advisory services.

# The Episode grouper















Multiple claim lines are linked to a single episode. Asynchronous information summarised into single health events. Clinical complexity retained.





### Clinically intuitive, rich patient views



Name: Mr M

Option: Galaxy Plus	Gender: Male	Age	: 86	Date joined: 1 Mar 2012			
Limited – r	major acute Acute additive	e Chronic - J	persistent C	hronic - intermittent	Organ failure		
	2012	2013	2014	2015	2016		
Cardiovascular							
Congestive cardiac failure							
Ischaemic heart disease							
Treated hypertension							
Angina pectoris							
Cardiac arrhythmia							
Pulmonary embolism							
Endocrine							
Lipid disorders							
Other hypothyroidism							
Disorders of fluid, electrolyte and acid-bas	se balance						
Musculoskeletal							
Osteoporosis without pathological fracture	e						
Arthritis							
Coxarthrosis							
Neurological							
Sleep Disorders							
Alzheimer's disease							
Polyneuropathy							
Digestive disorders							
Chronic ulcer with haemorrhage and/or p	erforation						
Diverticular disease of intestine							
Functional intestinal disorders							
Integumentary							
Vasculitis limited to skin							

### Disaggregate spend across episodes for individuals over time



Name: Mr M

Option: Galaxy Plus	Gender: Male	Age: 86		Date joined: 1 Mar		
Limited – n	najor acute Acute additive	Acute additive Chronic - pe		nronic - intermittent	Organ failure	
	2012	2013	2014	2015	2016	Cost
Cardiovascular						
Congestive cardiac failure						23 223.32
Ischaemic heart disease						13 746.49
Treated hypertension				193 471	.96 <	10 973.83
Angina pectoris						20 001.55
Cardiac arrhythmia						120 989.67
Pulmonary embolism						4 537.10
Endocrine						
Lipid disorders						35 154.00
Other hypothyroidism				126 371	.92 <	2 590.23
Disorders of fluid, electrolyte and acid-bas	se balance				9	88 627.69
Musculoskeletal						
Osteoporosis without pathological fracture	e					785.89
Arthritis				167 610	.49 — 🗧 📋	2 030.50
Coxarthrosis						164 794.10
Neurological						
Sleep Disorders						3 021.66
Alzheimer's disease				5 020	.95 -	306.09
Polyneuropathy						1 693.20
Digestive disorders						
Chronic ulcer with haemorrhage and/or pe	erforation					1 996.73
Diverticular disease of intestine				3 270	$\sim$ $\sim$	306.09
Functional intestinal disorders						968.17
Integumentary		1				
Vasculitis limited to skin						305.42
				i i		

### Understand how interaction is driven by episodes



Name: Mr M



### Improves risk prediction through built-in observed disease specific progression







- Inference analytics
- Improved disease management (different kind of ROI)
- Monitoring and alerts
  - Live, interactive dashboards
  - Product design considerations

Determine future episode relevance / significance

### Understand and treat patients according to their specific needs

Patient A Progressive Angina Costs: R50 000

45 year old male

Co-morbidities: Hypertension,

minimal

Relative risk index: 2.5

65 year old male

Co-morbidities: Congestive hearth failure,

Type I Diabetes, Vascular diseases, Renal

failure

Relative risk index: 30.5

Patient B Progressive Angina Costs: R500 000



### Observe developmental patterns (episode views) over time







A comprehensive toolbox that can be used to analyse healthcare data in the appropriate manner, with the necessary risk adjustment and grouping to arrive at the right conclusions in order to make the best decisions.




### This presentation is incomplete without the accompanying narrative

